AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3049227 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage analysis using three autosomal dominant models and three autosomal recessive models
Number of subjects: 0
Study 31678223 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Treadmill Training (2×/wk for 6 weeks)
Number of subjects: 19
Study 31678223 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Treadmill Training (10×/wk for 6 weeks)
Number of subjects: 19
Study 29622600 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibition
Number of subjects: 4853
Study 28365033 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin in elderly patients
Number of subjects: 3
Study 28365033 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin in patients with renal impairment
Number of subjects: 3
Study 28365033 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin in patients with hepatic impairment
Number of subjects: 3
Study 26437535 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 26
Study 26437535 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 26
Study 24095299 — intervention group
Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol 145 mg/m(2) every 14 days
Number of subjects: 70
Study 24095299 — intervention group
Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol 145 mg/m(2) every 21 days
Number of subjects: 70
Study 24095299 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study 21165807 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact step aerobic exercise (SA, n=15)
Number of subjects: 51
Study 21165807 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity lower body strength training (ST, n=16)
Number of subjects: 51
Study 21165807 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control (CON, n=20)
Number of subjects: 51
Study 18510609 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based IFOBT
Number of subjects: 640
Study 18510609 — intervention group
Group type: COMPARATOR
Intervention: M2-PK
Number of subjects: 640
Study 16594854 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual genetic risk counseling
Number of subjects: 211
Study 16594854 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychosocial counseling
Number of subjects: 211
Study 16594854 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 211
Study 14570527 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education intervention (GE)
Number of subjects: 250
Study 14570527 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education‐plus‐discussion intervention (GED)
Number of subjects: 250
Study 14570527 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 250
Study 10919899 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir (500 mg, three times daily)
Number of subjects: 110
Study 10919899 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir (800 mg, five times daily)
Number of subjects: 110
Study 8761985 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (10%)
Number of subjects: 10
Study 8761985 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (20%)
Number of subjects: 10
Study 8761985 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (30%)
Number of subjects: 10
Study 8761985 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (40%)
Number of subjects: 10
Study 8761985 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide (0%)
Number of subjects: 10
Study 8761985 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (0%, 10%, 20%, 30%, 40%)
Number of subjects: 10
Study 1451073 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionated radiation therapy (AHRT) at 48.0 Gy
Number of subjects: 304
Study 1451073 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionated radiation therapy (AHRT) at 54.4 Gy
Number of subjects: 304
Study 1451073 — intervention group
Group type: COMPARATOR
Intervention: Standard radiation therapy (RT) and bis-chloroethyl nitrosourea (BCNU) for patients 60 years or older
Number of subjects: 304
Study 6731323 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 1375
Study 6731323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1375
Study 30591391 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation with low-level laser therapy (LLLT)
Number of subjects: 26
Study 30591391 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LLLT)
Number of subjects: 26
Study 30591391 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study 29464587 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day vonoprazan
Number of subjects: 149
Study 29464587 — intervention group
Group type: COMPARATOR
Intervention: 30 mg/day lansoprazole
Number of subjects: 149
Study 29464587 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed bleeding
Number of subjects: 149
Study 27306921 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (specific dosage and duration not available)
Number of subjects: 0
Study 25281675 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM technology
Number of subjects: 76
Study 25281675 — intervention group
Group type: COMPARATOR
Intervention: Traditional preparation methods
Number of subjects: 76
Study 25281675 — intervention group
Group type: COMPARATOR
Intervention: No CAD/CAM technology
Number of subjects: 76
Study 22706944 — intervention group
Group type: EXPERIMENTAL
Intervention: HGI (High Glycaemic Index) meal (GI: 80)
Number of subjects: 9
Study 22706944 — intervention group
Group type: EXPERIMENTAL
Intervention: LGI (Low Glycaemic Index) meal (GI: 44)
Number of subjects: 9
Study 22706944 — intervention group
Group type: COMPARATOR
Intervention: Both HGI and LGI meals
Number of subjects: 9
Study 20920044 — intervention group
Group type: EXPERIMENTAL
Intervention: sitagliptin
Number of subjects: 37
Study 20920044 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 37
Study 20920044 — intervention group
Group type: EXPERIMENTAL
Intervention: intensive insulin therapy (IIT)
Number of subjects: 37
Study 18040529 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium inhalation
Number of subjects: 21
Study 18040529 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 21
Study 16120075 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 10
Study 16120075 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 10
Study 12390610 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (group A, n = 80)
Number of subjects: 160
Study 12390610 — intervention group
Group type: COMPARATOR
Intervention: Flunarizine (group F, n = 80)
Number of subjects: 160
Study 10192649 — intervention group
Group type: EXPERIMENTAL
Intervention: >= 1 drink/week
Number of subjects: 21041
Study 10192649 — intervention group
Group type: COMPARATOR
Intervention: < 1 drink/week
Number of subjects: 21041
Study 10192649 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 drink/week
Number of subjects: 21041
Study 10192649 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-4 drinks/week
Number of subjects: 21041
Study 10192649 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-6 drinks/week
Number of subjects: 21041
Study 10192649 — intervention group
Group type: EXPERIMENTAL
Intervention: >= 1 drink/day
Number of subjects: 21041
Study 7721268 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of bone mass by dual energy X‐ray absorptiometry of the hip, spine or forearm
Number of subjects: 0
Study 7721268 — intervention group
Group type: EXPERIMENTAL
Intervention: New markers specific for bone formation and bone resorption
Number of subjects: 0
Study 2287555 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet inflation at 5 minutes after cefazolin administration
Number of subjects: 0
Study 2287555 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet inflation at 2 minutes after cefazolin administration
Number of subjects: 0
Study 2287555 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet inflation at 1 minute after cefazolin administration
Number of subjects: 0
Study 2287555 — intervention group
Group type: COMPARATOR
Intervention: Comparison of soft tissue penetration between 5 and 1 minute
Number of subjects: 0
Study 6973989 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg fluproquazone
Number of subjects: 59
Study 6973989 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg fluproquazone
Number of subjects: 59
Study 31170178 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-real-time PCR testing for enterovirus
Number of subjects: 14928
Study 31170178 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotype distribution of enteroviruses
Number of subjects: 14928
Study 31170178 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis of enterovirus serotypes
Number of subjects: 14928
Study 31170178 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidemic incidence rates
Number of subjects: 14928
Study 31170178 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidemic peaks
Number of subjects: 14928
Study 28118533 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous belimumab 200 mg weekly
Number of subjects: 836
Study 28118533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 836
Study 25082346 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg QD
Number of subjects: 46
Study 23406311 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative carbohydrate drinks and postoperative polymeric supplement drinks
Number of subjects: 120
Study 23406311 — intervention group
Group type: COMPARATOR
Intervention: Placebo drinks
Number of subjects: 120
Study 21839898 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC (salmeterol/fluticasone)
Number of subjects: 0
Study 21839898 — intervention group
Group type: COMPARATOR
Intervention: MON (montelukast)
Number of subjects: 0
Study 19703126 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa5 vaccination
Number of subjects: 542
Study 19703126 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa5 re-vaccination at 4, 5, and 6 years of age
Number of subjects: 542
Study 19703126 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa5 or DTPwc primed children with verified pertussis infection
Number of subjects: 542
Study 19703126 — intervention group
Group type: COMPARATOR
Intervention: DTPa2 or DT group (not primed with fimbriae)
Number of subjects: 542
Study 19703126 — intervention group
Group type: COMPARATOR
Intervention: DTPa2 and DTPa3 vaccines
Number of subjects: 542
Study 19703126 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG anti-Fim2/3 levels > or =5 EU/ml
Number of subjects: 542
Study 16421426 — intervention group
Group type: EXPERIMENTAL
Intervention: NHL-BFM95 (no prophylactic cranial radiotherapy)
Number of subjects: 156
Study 16421426 — intervention group
Group type: COMPARATOR
Intervention: NHL-BFM90/86 (with prophylactic cranial radiotherapy)
Number of subjects: 156
Study 15313300 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%
Number of subjects: 90
Study 15313300 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 90
Study 15313300 — intervention group
Group type: COMPARATOR
Intervention: Placebo (balanced saline solution)
Number of subjects: 90
Study 11151742 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 2.1 mg kg‐1 body weight (low dose)
Number of subjects: 50
Study 11151742 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 4.3 mg kg‐1 body weight (medium dose)
Number of subjects: 50
Study 11151742 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 8.6 mg kg‐1 body weight (high dose)
Number of subjects: 50
Study 11151742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 9296412 — intervention group
Group type: EXPERIMENTAL
Intervention: Light wand intubation
Number of subjects: 40
Study 9296412 — intervention group
Group type: COMPARATOR
Intervention: Rigid laryngoscopy
Number of subjects: 40
Study 8160559 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable, as this is a review of clinical trials and does not specify a particular intervention.
Number of subjects: 100
Study 8160559 — intervention group
Group type: COMPARATOR
Intervention: Not applicable, as this is a review of clinical trials and does not specify a particular control.
Number of subjects: 100
Study 2871783 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevantolol 200 to 400 mg/day
Number of subjects: 139
Study 2871783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 31474282 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation condition (writing essays about personally important values)
Number of subjects: 163
Study 31474282 — intervention group
Group type: COMPARATOR
Intervention: Control condition (writing essays about personally unimportant values)
Number of subjects: 163
Study 31474282 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation condition
Number of subjects: 163
Study 29210953 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline Malate (CM) 8 g
Number of subjects: 12
Study 29210953 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study 26437670 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright neonatal resuscitator
Number of subjects: 87
Study 26437670 — intervention group
Group type: COMPARATOR
Intervention: Standard Laerdal neonatal resuscitator
Number of subjects: 87
Study 24095257 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (1.5 mA for 20 min over the right dlPFC)
Number of subjects: 42
Study 24095257 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 42
Study 22998687 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (ESO) treatment for 5 years
Number of subjects: 554
Study 22998687 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic antireflux surgery (LARS)
Number of subjects: 554
Study 20951306 — intervention group
Group type: EXPERIMENTAL
Intervention: WMTA at pH 7.4
Number of subjects: 64
Study 20951306 — intervention group
Group type: EXPERIMENTAL
Intervention: WMTA at pH 4.4
Number of subjects: 64
Study 20951306 — intervention group
Group type: EXPERIMENTAL
Intervention: Aureoseal at pH 7.4
Number of subjects: 64
Study 20951306 — intervention group
Group type: EXPERIMENTAL
Intervention: Aureoseal at pH 4.4
Number of subjects: 64
Study 17435678 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxoplasma-infected men
Number of subjects: 89
Study 17435678 — intervention group
Group type: COMPARATOR
Intervention: Non-infected men (control group)
Number of subjects: 89
Study 15905191 — intervention group
Group type: EXPERIMENTAL
Intervention: Mercaptopurine (MP) alone
Number of subjects: 82
Study 15905191 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate plus Mercaptopurine (MTX + MP)
Number of subjects: 82
Study 15905191 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrobenzylmercaptopurine ribonucleoside (NBMPR) in vitro
Number of subjects: 82
Study 14591851 — intervention group
Group type: EXPERIMENTAL
Intervention: malingering
Number of subjects: 60
Study 14591851 — intervention group
Group type: EXPERIMENTAL
Intervention: malinger-with-warning
Number of subjects: 60
Study 14591851 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 60
Study 9457819 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy (HFX RT) with a thoracic spinal cord dose of 50.4 Gy given via 1.2 Gy b.i.d. fractionation
Number of subjects: 300
Study 9457819 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemotherapy (CHT)
Number of subjects: 300
Study 7618725 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural lidocaine (2% lidocaine)
Number of subjects: 10
Study 7618725 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 10
Study 7618725 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lidocaine)
Number of subjects: 10
Study 2612558 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil 360 mg at 22.00 h
Number of subjects: 10
Study 2612558 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release verapamil 360 mg at 08.00 h
Number of subjects: 10
Study 2612558 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil 360 mg at night (24.00 h-06.00 h)
Number of subjects: 10
Study 589349 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical teams for psychiatric assessment
Number of subjects: 276
Study 589349 — intervention group
Group type: COMPARATOR
Intervention: Psychiatrists for psychiatric assessment
Number of subjects: 276
Study 30771362 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced NCMP letters
Number of subjects: 2642
Study 30771362 — intervention group
Group type: COMPARATOR
Intervention: Control letters
Number of subjects: 2642
Study 30771362 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report variables
Number of subjects: 2642
Study 28981543 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 4% chlorhexidine care
Number of subjects: 89
Study 28981543 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 89
Study 25939018 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Processing Therapy (CPT-C)
Number of subjects: 108
Study 25939018 — intervention group
Group type: COMPARATOR
Intervention: Group Present-Centered Therapy (PCT)
Number of subjects: 108
Study 23872500 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fructose diet
Number of subjects: 32
Study 23872500 — intervention group
Group type: COMPARATOR
Intervention: High-glucose diet
Number of subjects: 32
Study 21742012 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (4mg) with ketamine (0.04mg/kg)
Number of subjects: 40
Study 21742012 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum with ketamine (0.04mg/kg)
Number of subjects: 40
Study 21742012 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (4mg) with placebo
Number of subjects: 40
Study 21742012 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum with placebo
Number of subjects: 40
Study 17901240 — intervention group
Group type: EXPERIMENTAL
Intervention: EX‐C (exercise with a thermal clamp at 24 degrees C)
Number of subjects: 13
Study 17901240 — intervention group
Group type: EXPERIMENTAL
Intervention: EX‐H (exercise-induced heating at water temperature 36 degrees C)
Number of subjects: 13
Study 17901240 — intervention group
Group type: EXPERIMENTAL
Intervention: PA‐H (passive heating at 38.5 degrees C)
Number of subjects: 13
Study 17901240 — intervention group
Group type: COMPARATOR
Intervention: CON (control at 35 degrees C)
Number of subjects: 13
Study 16261517 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta050 (440 mg three times a day for 4 weeks, then 880 mg twice a day for 4 weeks)
Number of subjects: 54
Study 16261517 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta050
Number of subjects: 54
Study 12072677 — intervention group
Group type: EXPERIMENTAL
Intervention: Coupled plasma filtration adsorption plus hemodialysis (treatment A)
Number of subjects: 10
Study 12072677 — intervention group
Group type: COMPARATOR
Intervention: Continuous venovenous hemodiafiltration (treatment B)
Number of subjects: 10
Study 10190722 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA treatment
Number of subjects: 103
Study 7797061 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 0
Study 2224694 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose zidovudine therapy
Number of subjects: 0
Study 2224694 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose zidovudine therapy
Number of subjects: 0
Study 2224694 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine therapy
Number of subjects: 0
Study 426553 — intervention group
Group type: EXPERIMENTAL
Intervention: 6000 rads plus 5‐FU
Number of subjects: 106
Study 426553 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 rads plus 5‐FU
Number of subjects: 106
Study 426553 — intervention group
Group type: COMPARATOR
Intervention: 6000 rads alone
Number of subjects: 106
Study 31705570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine and daunorubicin (7 + 3)
Number of subjects: 32
Study 31705570 — intervention group
Group type: COMPARATOR
Intervention: Clofarabine
Number of subjects: 32
Study 27393080 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (50 mg/day orally) with EE/LNG
Number of subjects: 81
Study 27393080 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (50 mg/day orally) with EE/DRSP
Number of subjects: 81
Study 27393080 — intervention group
Group type: COMPARATOR
Intervention: Placebo with EE/LNG
Number of subjects: 81
Study 27393080 — intervention group
Group type: COMPARATOR
Intervention: Placebo with EE/DRSP
Number of subjects: 81
Study 25976296 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 51
Study 25976296 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic cranial irradiation (no PCI)
Number of subjects: 51
Study 23111852 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 655
Study 23111852 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 655
Study 23111852 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with fosinopril and pravastatin
Number of subjects: 655
Study 23111852 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 655
Study 21797983 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy (ICBT)
Number of subjects: 78
Study 21797983 — intervention group
Group type: COMPARATOR
Intervention: Control group (online discussion group)
Number of subjects: 78
Study 19564523 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA-detected cancers
Number of subjects: 3535
Study 19564523 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA-detected cancers with Gleason score <7
Number of subjects: 3535
Study 19564523 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA-detected cancers with Gleason score 7 or more
Number of subjects: 3535
Study 19564523 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between detection mode and Gleason score
Number of subjects: 3535